Fu Hong Han Lin (02696): An international multi-center phase 2 clinical study on injectable HLX43 (targeted PD-L1 antibody conjugate drug) for the treatment of advanced non-small cell lung cancer completed the first patient administration in China

According to Zhitong Finance App, Fu Hong Han Lin (02696) announced that recently, an international multi-center phase 2 clinical study with HLX43 (targeted PD-L1 antibody conjugate drug) (HLX43) in advanced non-small cell lung cancer (NSCLC) patients completed the first patient administration in China (excluding Hong Kong, Macao and Taiwan regions of China, same below).

This study is an open, international multi-center phase 2 clinical trial evaluating HLX43 in advanced non-small cell lung cancer (NSCLC) patients. The purpose is to evaluate the efficacy and safety of HLX43 in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two stages: the first phase will conduct dose exploration to select the appropriate HLX43 dose for the second phase study; the second phase is a single-arm, multi-center phase 2 clinical study. The main purpose of this study was to evaluate the clinical efficacy of HLX43 in advanced non-small cell lung cancer (NSCLC); the main end point of the study was the objective remission rate assessed by the Blind Independent Center Review Committee according to the ReciST v1.1 standard.